Supplementary File

Identifying RA patients with moderate disease activity at risk of significant radiographic progression despite methotrexate treatment

B. Fautrel, H. Nab, Y. Brault, G. Gallo

Contents

Table S1 Patients with SRP by baseline erosion score

Figure S1 Multivariate analysis: tertile baseline predictors of SRP after 3 years in patients with moderate disease activity despite MTX treatment
**Table S1** Patients with SRP by baseline erosion score

| Baseline erosion score | SRP after 2 years, n (%) | SRP after 3 years, n (%) |
|------------------------|--------------------------|--------------------------|
|                        | Fisher's Exact Test P  | Phi coefficient          |
|                        | value                   |                          |
| 0                      | No  | Yes | 1.000 | –0.003 | No | Yes | 0.794 | –0.026 |
| >0                     | 14 (73.7) | 5 (26.3) | 57 (74.0) | 20 (26.0) | 12 (63.2) | 7 (36.8) | 51 (66.2) | 26 (33.8) |
| 0                      | No  | Yes | 0.811 | 0.072 | No | Yes | 0.118 | 0.211 |
| >0–<4                  | 14 (73.7) | 5 (26.3) | 16 (80.0) | 4 (20.0) | 17 (85.0) | 3 (15.0) | 34 (59.6) | 23 (40.4) |
| ≥4                     | 41 (71.9) | 16 (28.1) | 34 (59.6) | 23 (40.4) | 34 (59.6) | 23 (40.4) | 34 (59.6) | 23 (40.4) |

The phi coefficient is a measure of association derived from the Pearson chi-square. SRP, significant radiographic progression.

**Figure S1** Multivariate analysis: tertile baseline predictors of SRP after 3 years in patient with moderate disease activity despite MTX treatment

SRP at 3 years

SRP, significant radiographic progression; MTX, methotrexate; RF, rheumatoid arthritis; CRP, C-reactive protein; CI, confidence interval.